2021
Racial and Ethnic Disparities in Comorbidities in Youth With Type 2 Diabetes in the Pediatric Diabetes Consortium (PDC).
Bacha F, Cheng P, Gal RL, Beaulieu LC, Kollman C, Adolph A, Shoemaker AH, Wolf R, Klingensmith GJ, Tamborlane WV. Racial and Ethnic Disparities in Comorbidities in Youth With Type 2 Diabetes in the Pediatric Diabetes Consortium (PDC). Diabetes Care 2021, 44: 2245-2251. PMID: 34475033, DOI: 10.2337/dc21-0143.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseType 2 diabetesNon-Hispanic blacksPediatric Diabetes ConsortiumFatty liver diseaseWorse metabolic controlRacial-ethnic disparitiesNon-Hispanic white youthManagement of youthSubsequent comorbiditiesDiabetic ketoacidosisInitial presentationLiver diseaseMean ageRegistry participantsMedical recordsC-peptideClinical dataDiabetesMetabolic controlHealth outcomesRacial-ethnic differencesEthnic disparitiesComorbiditiesRacial-ethnic groups
2015
C‐peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry
Gregg B, Connor CG, Cheng P, Ruedy KJ, Beck RW, Kollman C, Schatz D, Cengiz E, Tamborlane WV, Klingensmith GJ, Lee JM, Consortium F. C‐peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2015, 17: 274-280. PMID: 25940861, DOI: 10.1111/pedi.12280.Peer-Reviewed Original ResearchConceptsC-peptide levelsC-peptide measurementsLower body mass indexPediatric type 2 diabetesInsulin-treated patientsEndogenous insulin secretionPediatric diabetes centersC-peptide valuesBody mass indexType 2 diabetesT2D durationInsulin therapyClinical factorsDiabetes CenterClinic registryMass indexC-peptideInsulin secretionInsulin treatmentLarge cohortT2DMetabolic controlType 2Biologic dataRegistryCGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes
Buckingham B, Cheng P, Beck RW, Kollman C, Ruedy KJ, Weinzimer SA, Slover R, Bremer AA, Fuqua J, Tamborlane W, for the Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups. CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes. Diabetologia 2015, 58: 1167-1174. PMID: 25773405, PMCID: PMC4416994, DOI: 10.1007/s00125-015-3559-y.Peer-Reviewed Original ResearchConceptsC-peptide levelsType 1 diabetesHigher C-peptide levelsC-peptideGlucose levelsTime pointsGlucose valuesMixed meal tolerance testAims/hypothesisThe aimCGM glucose levelsC-peptide responseWeeks of diagnosisOnset of diabetesLower glucose variabilityConclusions/interpretationInMethodsA secondary analysisSensor glucose levelsCGM glucose valuesAdditional time pointsHypothesisThe aimGlucose variabilityTolerance testContinuous glucose monitoring dataInsulin secretionCGM metrics
2005
Predictors of Changes in Glucose Tolerance Status in Obese Youth
Weiss R, Taksali SE, Tamborlane WV, Burgert TS, Savoye M, Caprio S. Predictors of Changes in Glucose Tolerance Status in Obese Youth. Diabetes Care 2005, 28: 902-909. PMID: 15793193, DOI: 10.2337/diacare.28.4.902.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testImpaired glucose toleranceType 2 diabetesNormal glucose toleranceGlucose tolerance statusGlucose toleranceObese youthPredictors of changeObese childrenTolerance statusHigh riskGlucose tolerance testSevere obesityAfrican American descentTolerance testInsulin sensitivityC-peptideGlucose levelsDiabetesAnthropometric predictorsWeight changeAfrican American backgroundsPredictorsBaselineSubjects
1994
Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults.
Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. Journal Of Clinical Investigation 1994, 93: 1131-1139. PMID: 8132753, PMCID: PMC294058, DOI: 10.1172/jci117065.Peer-Reviewed Original ResearchConceptsRecombinant human insulin-like growth factorInsulin-like growth factorHuman insulin-like growth factorMiddle-aged subjectsC-peptideYoung subjectsBasal IGF-I levelsHealthy middle-aged subjectsGlucose uptakeGrowth factorAdverse metabolic changesFree fatty acid levelsIGF-I levelsRelative insulin deficiencyEuglycemic clamp studiesFat oxidation rateDose-response relationshipFatty acid levelsInsulin-induced stimulationMiddle-aged adultsBasal insulinInsulin deficiencyMetabolic effectsClamp studiesRhIGF
1992
Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism
Boulware SD, Tamborlane WV, Matthews LS, Sherwin RS. Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism. American Journal Of Physiology 1992, 262: e130-e133. PMID: 1733244, DOI: 10.1152/ajpendo.1992.262.1.e130.Peer-Reviewed Original ResearchConceptsInsulin-like growth factor IIGF-I levelsGrowth factor IInsulin secretionTotal IGF-I levelsFree IGF-I levelsAcid metabolismRecombinant human insulin-like growth factor IFactor IAmino acid metabolismFree fatty acid metabolismHealthy nonobese subjectsHuman insulin-like growth factor IHepatic glucose productionBranched-chain amino acidsExogenous glucose infusionFatty acid metabolismGlucagon levelsInsulin levelsNonobese subjectsContinuous infusionConcomitant inhibitory effectTwo- to threefold increaseC-peptideGlucose infusion